Is Celcuity Inc. (CELC) a Buy, Sell, or Hold?
Celcuity Inc.
NASDAQ:CELC
$111.05 USD
$7.26 (6.99%)
- Volume
- 2.24M
- Average Volume
- 1.38M
- Market Capitalization
- $5.42B
- P/E Ratio
- -28.55
- Dividend Yield
- 0.00%
- Price Target
- $157.00
- Year High
- $151.02
- Year Low
- $13.37
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $12.31
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Brian F. Sullivan |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | CELC |
| CUSIP | 15102K100 |
| CIK | 0001603454 |
| Web | https://www.celcuity.com |
| Phone | 763 392 0767 |
| Currency | USD |
| Employees | 155 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 3.65 |
| Payout Ratio | 0.00 |
| Current Ratio | 12.31 |
| Quick Ratio | 12.31 |
| Cash Ratio | 4.37 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -3.18 |
| Price / Cash Flow | -31.32 |
| Price / Book | 113.00 |
Price Target and Rating
| Average Stock Price Forecast | $157.00 |
| High Stock Price Forecast | $171.00 |
| Low Stock Price Forecast | $110.00 |
| Forecast Upside/Downside | -29.27% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 12 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-3.78 |
| Trailing P/E Ratio | -28.55 |
| PEG Ratio | 1.19 |
| P/E Growth | 1.19 |
| Net Income | $-177.04M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -244.61% |
| Return on Assets | -47.03% |
Financials Score
| AltmanZ Score | 6.51 |
| Piotroski Score | 2.00 |
| Working Capital | 375.72M |
| Total Assets | 410.16M |
| Ebit | -172.84M |
| Market Cap | 5.06B |
| Total Liabilities | 356.64M |
Poll Results
About Celcuity Inc. (NASDAQ:CELC) Stock
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN. ...
2026-07-14 16:53:00
MINNEAPOLIS, July 14, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, today announced that the U.S. Food and Drug Administration (“FDA”) approved REVTORPYK™ (gedatolisib) for the treatment of patients with hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”), locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting. REVTORPYK is the only inhibitor of class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2 to receive FDA approval.
2026-06-10 15:32:13
Celcuity Inc. (CELC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
2026-06-03 22:13:20
MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) ("Celcuity" or the "Company"), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced the pricing of its upsized underwritten public offering of $500,000,000 aggregate principal amount of its 0.
2026-06-03 22:13:00
MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (“Celcuity” or the “Company”), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced the pricing of its upsized underwritten public offering of $500,000,000 aggregate principal amount of its 0.250% convertible senior notes due 2032 (the “Convertible Notes”). The aggregate principal amount of the offering was increased from the previously announced offering size of $400,000,000.
Celcuity: Selloff On Yesterday's Data Unwarranted - Buy Rating Upheld
2026-06-03 09:33:26
Celcuity (CELC) shares dropped over 25% despite Phase 3 VIKTORIA-1 data confirming gedatolisib's best-in-class efficacy in advanced breast cancer. Gedatolisib demonstrated superior progression-free survival and objective response rates versus current standards, supporting blockbuster potential in a $6bn market. FDA approval for HR+/HER2- PIK3CA wild-type breast cancer is expected by July 2026, with a supplementary NDA for the mutant cohort planned.
Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032
2026-06-03 07:19:12
MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) ("Celcuity" or the "Company"), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced a proposed underwritten public offering of $400,000,000 aggregate principal amount of its convertible senior notes due 2032 (the "Convertible Notes").
Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032
2026-06-03 07:19:00
MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (“Celcuity” or the “Company”), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced a proposed underwritten public offering of $400,000,000 aggregate principal amount of its convertible senior notes due 2032 (the “Convertible Notes”).
2026-06-02 16:11:55
Celcuity Inc. (CELC) Discusses VIKTORIA-1 Trial Results for PIK3CA Mutant Advanced Breast Cancer and Gedatolisib Efficacy Transcript
Frequently Asked Questions
-
What is the current Celcuity Inc. (CELC) stock price?
-
Celcuity Inc.(NASDAQ:CELC) stock price is $111.05 in the last trading session. During the trading session, CELC stock reached the peak price of $151.02 while $13.365 was the lowest point it dropped to. The percentage change in CELC stock occurred in the recent session was 6.99% while the dollar amount for the price change in CELC stock was $7.26.
-
CELC's industry and sector of operation?
-
The NASDAQ listed CELC is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CELC?
-
Igor Gorbatchevsky | Chief Medical Officer
Jodi Sievers | Head of Investor Relations & Corporate Communications
Vicky Hahne | Chief Financial Officer
Sheri Smith | Acting Head of Clinical Operations
Lance G. Laing | Co-Founder, Chief Science Officer, Vice President, Secretary & Director -
How many employees does CELC have?
-
Number of CELC employees currently stands at 155. CELC operates from 16305 36th Avenue North, Minneapolis, MN 55446, US.
-
Link for CELC official website?
-
Official Website of CELC is: https://www.celcuity.com
-
How do I contact CELC?
-
CELC could be contacted at phone #763 392 0767 and can also be accessed through its website. CELC operates from 16305 36th Avenue North, Minneapolis, MN 55446, US.
-
How many shares of CELC are traded daily?
-
The average number of CELC shares traded daily for last 3 months was 1.38M.
-
What is the market cap of CELC currently?
-
The market value of CELC currently stands at $5.42B with its latest stock price at $111.05